A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

被引：8
|
作者：
Cohen, Ezra E. W.
Rischin, Danny
Pfister, David G.
Vermorken, Jan Baptist
Zhao, Yufan
Gowda, Hema
Ge, Joy Yang
Jin, Fan
Harrington, Kevin J.
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Peter MacCallum Canc Ctr, East Melbourne, Australia
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Antwerp Univ Hosp, Dept Med Oncol, Edegem, Belgium
[5] Incyte Corp, Wilmington, DE USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Inst Canc Res, Sutton, Surrey, England
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS6090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6090
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
    Obara, G.
    Sun, J.
    Loo, D.
    Bohac, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S814 - S814
  • [22] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
    Gui, L.
    Chen, X.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1609 - S1610
  • [23] Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1524 - S1524
  • [24] Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra E. W.
    Harrington, Kevin Joseph
    Licitra, Lisa F.
    Rischin, Danny
    Zhu, Ying
    Lee, Chooi Peng
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal H.
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [26] Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress
    Sun, J.
    Enzinger, P.
    Adenis, A.
    Shah, M.
    Kato, K.
    Bennouna, J.
    Doi, T.
    Hawk, N.
    Yu, L.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S352 - S352
  • [27] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA IN COLOMBIA
    Urrego-Reyes, J.
    Lopez, C.
    Marrugo, A. C.
    Wurcel, V
    Khandelwal, A.
    Patel, A.
    Black, C.
    VALUE IN HEALTH, 2023, 26 (06) : S95 - S95
  • [28] Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
    Victoria Wurcel
    Diana Chirovsky
    Rebekah Borse
    Juan Ignacio Altuna
    Fernando Carabajal
    Jyotika Gandhi
    Advances in Therapy, 2021, 38 : 2613 - 2630
  • [29] Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
    Wurcel, Victoria
    Chirovsky, Diana
    Borse, Rebekah
    Altuna, Juan Ignacio
    Carabajal, Fernando
    Gandhi, Jyotika
    ADVANCES IN THERAPY, 2021, 38 (05) : 2613 - 2630
  • [30] Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
    Borse, Rebekah H.
    Ramakrishnan, Karthik
    Gandhi, Jyotika
    Dhankhar, Praveen
    Chirovsky, Diana
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 954 - 965
12345